Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Launxp Biomedical CoROCO:6876 -1.23%17 EV-to-EBITDA is -0.91 as of Sep. 05, 2026. GuruFocus rates ROCO:6876 with a GF Score™ of 17/100. The stock has 4 warning signs investors should review. Among 403 Biotechnology companies, Launxp Biomedical Co ranks worse than 248138.71% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Launxp Biomedical Co's enterprise value is NT$401.46 Mil.
Launxp Biomedical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-441.68 Mil. Therefore, Launxp Biomedical Co's EV-to-EBITDA for today is -0.91.
The historical rank and industry rank for Launxp Biomedical Co's EV-to-EBITDA or its related term are showing as below:
ROCO:6876'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.27 Med: -7.08 Max: -0.87
Current: -0.91
During the past 6 years, the highest EV-to-EBITDA of Launxp Biomedical Co was -0.87. The lowest was -9.27. And the median was -7.08.
ROCO:6876's EV-to-EBITDA is ranked worse than 100% of 403
companies
in the Biotechnology industry
Industry Median: 13.7
vs ROCO:6876: -0.91
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Launxp Biomedical Co (ROCO:6876) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Launxp Biomedical Co's PE Ratio (TTM) for today is calculated as:
Launxp Biomedical Co's share price for today is NT$12.05.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Launxp Biomedical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-6.736.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Launxp Biomedical Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6876 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Launxp Biomedical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Launxp Biomedical Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Launxp Biomedical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Launxp Biomedical Co's EV-to-EBITDA falls into.
Launxp Biomedical Co's current Enterprise Value is NT$401.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Launxp Biomedical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-441.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Launxp Biomedical Co (ROCO:6876) has a EV-to-EBITDA of -0.91 as of Sep. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Launxp Biomedical Co. According to the industry distribution chart, Launxp Biomedical Co ranks #999999 out of 403 companies in the Biotechnology industry.
Is Launxp Biomedical Co's EV-to-EBITDA too high?
Launxp Biomedical Co's current EV-to-EBITDA is -0.91. Based on the distribution chart, Launxp Biomedical Co ranks #999999 out of 403 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Launxp Biomedical Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Launxp Biomedical Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Launxp Biomedical Co ranks #999999 out of 403 companies for EV-to-EBITDA. This places Launxp Biomedical Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Launxp Biomedical Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Launxp Biomedical Co's current EV-to-EBITDA is -0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Launxp Biomedical Co stock overvalued right now?
Launxp Biomedical Co (ROCO:6876) has a current EV-to-EBITDA of -0.91. The current EV-to-EBITDA is -0.91. Launxp Biomedical Co's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Launxp Biomedical Co (ROCO:6876), the current EV-to-EBITDA is -0.91 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Launxp Biomedical Co Ltd is a company that researches, designs and develops Cancer drug rapid screening platform and Early development evaluation and technology licensing of generic drugs for cancer treatment. The company mainly focuses on the screening of development drugs, formulation of development strategies, project management, planning and execution of regulations and clinical trials, etc.
17GF Score
Get the complete analysis for ROCO:6876
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6876 has been successfully added to your 
